source
- Drugmakers Rethink Launch Strategies as MFN Pricing Rules Shake MarketA new Numerof & Associates report says that the rollout of Most Favored Nation (MFN) pricing rules is forcing drugmakers to overhaul how they choose launch markets. Executives surveyed said the Un…
- FDA places partial hold on Biohaven epilepsy drug BHV-7000 amid $350 million licensing dealThe U.S. Food and Drug Administration issued a partial clinical hold on enrollment for Biohaven’s epilepsy candidate BHV-7000 after rodent studies raised questions about drug metabolites. The hold…